RE:THTX for retail investorsGood start!!!I agree they need to treat the retail investors in the same way as you would in any retail businesses.
I would limit the management overview on the newly arrived CEO from PFE with accomplishments since he joined!!!
Reputation as a top line CEO and now also ialso landed FDA S approval for Clinical Trials in 2 multi billion potential drugs
Take a break tonight and enjoy the Super Bowl!!!
quote=scarlet1967]
The company’s CEO have bachelor of science in biochemistry, CFO has master of business science, CMO has Ph.D. in biochemistry and General Manager in EU has Bachelor’s and Master’s degrees Between just four of them they have over 100 years of management experience in the industry.
Their research and development programs includes Cancer programs and None Alcoholic Steatohepatitis NASH (fatty liver disease).
ONCOLOGY
Their cancer drugs TH 1902 and TH 1904 are peptides (small proteins), the innovative approach for the cancer programs is based on a technology to deliver therapeutic agents to the organs. These peptides bind to anticancer agents they also bind to receptors (sortilin) which are commonly presented in many cancer types, this receptor get attached and surrounded by cancer cell membrane and enter the cell and form a spherical structure, later on the skin of that structure breaks down and release the receptor inside the cancer cells so the anticancer agents kill the cancer cells. The advantage of this technique versus other anticancer approaches is as a portion of other drugs will be resisted by cell membrane therefore it will be less concentration of their drugs which manages to enter the cancer cells.
Also their cancer technology inhibits vascular mimicry which is the progress the tumor cells organize themselves to a channel to provide blood to other cancer cells.
The beauty of this technology is that it can deliver other therapeutic agents to the targeted cell although the company now only exploring this mechanism of action on anti-cancer agents.
This technology can be used to treat various cancer types such as Melanoma(market size $12 billion by 2025), Pancreatic cancer( market size $4 billion by 2025) Colorectal cancer(market size $17billion by 2025) Endometrial cancer(market size 12 billion by 2027), Triple Negative Breast Cancer (Market size $55 billion by 2027) , Ovarian cancer(market size $3 billion by 2022) Neuroendocrine tumors(market size over 2 $ billion), Lung cancer(market size $37 billion), Soft tissue cancer( market size $3,6 billion) so between now and 2027 the combined market opportunity would be about $146 billion! The company recently got Fast Track Designation which only be approved by FDA for drugs which are under development for unmet conditions, this designation accelerate the trial progress and finally the potential approval will be faster and sooner. They are scheduled to start the trial in March this year.
NASH
Tesamorelin directly stimulate production of Growth Hormone which reduces Visceral fat (fat round the body’s organ), decreases storage of fat, improve energy production by cells, decreases inflammation.
The drug indirectly also stimulate production of Insulin-like Growth factor-1 in liver which decrease insulin resistance( less liver fat), decreases liver inflammation and deactivate liver cells which cause infection.
Also it was recently proved that Tesamorelin has inhibiting effect on pro inflammatory proteins causing inflammation if untreated causing infections. Their treatment approach is innovative while other approaches have failed for more than a decade.
NASH is a lethal disease with growing prevalence globally with no approved drug to date, as per company’s presentation only in the US there were over 16 million NASH patients in 2019 which is projected to reach 27 million patients by 2030. NASH market size globally was over $1 billion in 2017 and projected to reach over 21 billion in 2025.
The have patent coverage for Tesamorelin in NASH in the US and Europe and considering extending the protection to other parts of the world.
The company is scheduled to start the Phase 3 NASH trial by end of third quarter this year.
LEGACY DRUGS
They have two approved drugs currently commercialized, Trogarzo is an antiviral drug with long lasting effect treating patients with HIV and is currently commercialized in the US and Germany, will be launched in 4 other European countries and Israel.
Tesamorelin is treating Liodysrophyfor HIV patients (abnormal amount/distribution of fat) currently commercialized in the North America.
Last quarter they had record sales despite the Covid19 pandemic and projected to increase the sales by over %240 in the next 4 years.
[/quote]